1. White, RH . The epidemiology of venous thromboembolism. Circulation 2003; 107(Suppl I): I4–8.
Google Scholar | Medline2. Hull, RD, Hirsh, J, Carter, CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. Ann Intern Med 1985; 102: 21–28.
Google Scholar | Crossref | Medline3. Kakkar, VV, Howe, CT, Flanc, C, et al. Natural history of postoperative deep-vein thrombosis. Lancet 1969; 294: 230–233.
Google Scholar | Crossref4. Snow, V, Qaseem, A, Barry, P, et al. Management of venous thromboembolism: a clinical practice guideline from the American college of physicians and the American academy of family physicians. Ann Intern Med 2007; 146: 204–210.
Google Scholar | Crossref | Medline | ISI5. GruberFridrich, UF, Duckert, F, Fridrich, R, et al. Prevention of postoperative thromboembolism by dextran 40, low doses of heparin, or xantinol nicotinate. Lancet 1977; 1: 207–10.
Google Scholar | Medline6. He, L, Wang, J, Nan, L, et al. Clinical report on pharmacological prevention of deep vein thrombosis after radical resection of abdominal tumors. Int J Clin Med 2014; 5(1): 28–31.
Google Scholar | Crossref7. Neu, B, Wenby, R, Meiselman, HJ. Effects of dextran molecular weight on red blood cell aggregation. Biophysical J 2008; 95: 3059–3065.
Google Scholar | Crossref | Medline8. Engeset, J, Stalker, AL, Matheson, NA. Effects of dextran 40 on erythrocyte aggregation. Lancet 1966; 287: 1124–1127.
Google Scholar | Crossref9. Sobel, M, Adelman, B, Greenfield, LJ. Dextran 40 reduces heparin-mediated platelet aggregation. J Surg Res 1986; 40: 382–387.
Google Scholar | Crossref | Medline10. Aberg, M, Hedner, U, Bergentz, SE. Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surgery 1978; 189: 243–7.
Google Scholar | Crossref11. Tsao, CH, Krajewski, DV. Effect of dextran on platelet activation by polymerizing fibrin. Am J Pathol 1982; 106: 1–7.
Google Scholar | Medline12. Clagett, GP, Anderson, FA, Heit, J, et al. Prevention of venous thromboembolism. Chest 1995; 108: 312S–334S.
Google Scholar | Crossref | Medline | ISI13. Barritt, DW, Jordan, SC. Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960; 275: 1309–1312.
Google Scholar | Crossref14. Salzman, EW, Hirsh, J, Marder, VJ. Treatment of venous thromboembolism. In: Colman, RW, Hirsh, J, Marder, VJ, et al. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott, 1993, pp. 1346–1366.
Google Scholar15. Lensing, AWA, Prins, MH, Davidson, BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601–607.
Google Scholar | Crossref | Medline16. Grönwall, A, Ingelman, B. Dextran as a substitute for plasma. Nature 1945; 155: 45.
Google Scholar | Crossref17. Langdell, RD, Adelson, EA, Furth, FW, et al. Dextran and prolonged bleeding time. J Am Med Assoc 1958; 166: 346–351.
Google Scholar | Crossref | Medline18. Carbone, JV, Furth, FW, Russell, S, et al. An hemostatic defect associated with dextran infusion. Exp Biol Med 1954; 85: 101–103.
Google Scholar | SAGE Journals | ISI19. Abir, F, Barkhordarian, S, Sumpio, BE. Efficacy of dextran solutions in vascular surgery. Vasc Endovascular Surg 2004; 38: 483–491.
Google Scholar | SAGE Journals20. Riva, FMG, Chen, YC, Tan, NC, et al. The outcome of prostaglandin-E1 and dextran-40 compared to no antithrombotic therapy in head and neck free tissue transfer: analysis of 1,351 cases in a single center. Microsurgery 2012; 32: 339–343.
Google Scholar | Crossref | Medline21. Clagett, GP, Reisch, JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227–240.
Google Scholar | Crossref | Medline | ISI22. Baldwin, AL, Wu, NZ, Stein, DL. Endothelial surface charge of intestinal mucosal capillaries and its modulation by dextran. Microvasc Res 1991; 42: 160–178.
Google Scholar | Crossref | Medline23. Bergentz, SE . Dextran in the prophylaxis of pulmonary embolism. World J Surg 1978; 2: 19–24.
Google Scholar | Crossref | Medline24. Noorman, F, Barrett-Bergshoeff, MM, Bekkers, M, et al. Inhibition of mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) by dextran: a new explanation for its antithrombotic effect. Thromb Haemost 1997; 78: 1249–1254.
Google Scholar | Crossref | Medline25. Hattey, E, Haumer, M, Griffiths, MR, et al. Plasminalpha2- antiplasmin complexes (plasmin-plasmin inhibitor complexes). In: Jesperson, J, Bertina, RM, Haverkate, F (eds). Laboratoy techniques in thrombosis—a manual. (2nd revised ed of ECAT Assay Procedures). Dordrecht: The Netherlands: R Kluwer Academic Publishers, 1999, pp. 254–274.
Google Scholar26. Jones, CI, Payne, DA, Hayes, PD, et al. The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo. J Vasc Surg 2008; 48: 715–722.
Google Scholar | Crossref | Medline27. Gruber, UF . Dextran and the prevention of postoperative thromboembolic complications. Surg Clin North America 1975; 55: 679–696.
Google Scholar | Crossref | Medline28. Gallus, AS, Hirsh, J. Prevention of venous thromboembolism. Semin Thrombosis Hemostasis 1976; 2: 232–90.
Google Scholar | Crossref | Medline29. Bergqvist, D . Dextran in the prophylaxis of deep-vein thrombosis. JAMA 1987; 258: 324–325.
Google Scholar | Crossref | Medline30. Zinderman, CE, Landow, L, Wise, RP. Anaphylactoid reactions to dextran 40 and 70: reports to the United States food and drug administration, 1969 to 2004. J Vasc Surg 2006; 43: 1004–1009.
Google Scholar | Crossref | Medline31. Ljungström, KG, Renck, H, Strandberg, K, et al. Adverse reactions to dextran in Sweden 1970-1979. Acta Chir Scand 1983; 149: 253–262.
Google Scholar | Medline32. Gruber, UF, Saldeen, T, Brokop, T, et al. Incidences of fatal postoperative pulmonary embolism after prophylaxis with dextran 70 and low-dose heparin: an international multicentre study. BMJ 1980; 280: 69–72.
Google Scholar | Crossref | Medline33. Abir, F, Barkhordarian, S, Sumpio, BE. Efficacy of dextran solutions in vascular surgery. Vasc Endovascular Surg 2004; 38: 483–491.
Google Scholar | SAGE Journals34. Stevens, SM, Woller, C.SC, Kreuziger, LB, et al. Antithrombotic therapy for VTE disease second update of the CHEST guideline and expert panel report. Chest 2021; 2(21): S001201506–36923.
Google Scholar